title: Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women.
abstract: Medroxyprogesterone acetate (MPA) is widely known for its use in combination hormone therapy for postmenopausal women. However, MPA is also commonly used in young women for contraception and treatment of a number of gynecological conditions. Despite its widespread use, the cardiovascular effects of MPA in young women are unclear. Therefore, the purpose of this study was to determine the acute effects of MPA when used in combination with estradiol on markers of cardiovascular risk in young women. We suppressed endogenous estrogens and progesterone in 10 premenopausal women using a gonadotropin-releasing hormone antagonist (GnRHa) for 10 days. On day 4 of GnRHa subjects received 0.1 mg of estradiol (GnRHa+E(2)), and on day 7 5 mg of MPA was added (GnRHa+E(2)+MPA). Endothelium-dependent vasodilation and endothelium-independent vasodilation of the brachial artery, lipids, homocysteine, high-sensitivity C-reactive protein, and endothelin-1 were assessed during treatment with GnRHa, GnRHa+E(2), and GnRHa+E(2)+MPA. Four additional subjects were tested to validate the efficacy of the GnRHa model and confirm the findings. Endothelium-dependent vasodilation was greater during GnRHa+E(2) than during GnRHa or GnRHa+E(2)+MPA (P = 0.006). Endothelin-1 was lower during GnRHa+E(2) than GnRHa alone (P = 0.039). Endothelin-1 increased with the addition of MPA and was not significantly different from GnRHa alone. There were no differences in the other markers of cardiovascular risk between hormone treatment days. These data suggest that acute MPA administration negates the beneficial effects of estradiol on endothelium-dependent vasodilation in young women. In addition, these data suggest that estradiol decreases endothelin-1 concentrations and the addition of MPA may counteract the effect of estradiol on endothelin-1.
authors.affiliation: University of Oregon, Eugene, OR 97403, USA.
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Meendering
authors.forename: Britta N
authors.initials: BN
authors.lastname: Torgrimson
authors.forename: Nicole P
authors.initials: NP
authors.lastname: Miller
authors.forename: Paul F
authors.initials: PF
authors.lastname: Kaplan
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Minson
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D001916:Brachial Artery / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000187:drug effects*; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006339:Heart Rate / Q000187:drug effects; D006710:Homocysteine / Q000097:blood; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007279:Injections, Subcutaneous; D008055:Lipids / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology; D015203:Reproducibility of Results; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D015415:Biomarkers; D003271:Contraceptive Agents, Female; D004967:Estrogens; D006727:Hormone Antagonists; D008055:Lipids; D009842:Oligopeptides; D006710:Homocysteine; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D002097:C-Reactive Protein; D017258:Medroxyprogesterone Acetate